精准肝脏外科时代肝癌多学科治疗*

doi:10.3969/j.issn.1672-5069.2015.02.004

Abstract

Jia Weidong. Multidisciplinary treatments for patients with hepatocellular carcinoma in the era of precise liver surgery[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 120-123.

[1] 荚卫东.精准肝切除治疗肝细胞癌关键技术. 中国普通外科杂志,2014,23（1）:1-5.
[2] 董家鸿,黄志强. 倡导精准肝脏外科重现普罗米修斯神话. 中华消化外科杂志,2010,9（1）:4-5.
[3] 许戈良,荚卫东,李建生,等. 应用精细肝脏外科理念治疗原发性肝癌53例. 世界华人消化杂志,2010,18（17）:1824-1828.
[4] 仇毓东,朱新华,徐庆祥,等. 精准肝切除术治疗原发性肝癌的疗效评价. 中华消化外科杂志,2010,9（1）:1-3.
[5] 中华消化外科杂志编辑部. 精准肝脏外科专题讨论. 中华消化外科杂志,2014,13（6）:419-430.
[6] Fan ST. Precise hepatectomy guided by the middle hepatic vein. Hepatobiliary Pancreat Dis Int,2007,6（4）:430-434.
[7] 许戈良. 精细肝脏外科的发展. 国际外科学杂志,2008,35（2）:73-75.
[8] 董家鸿,黄志强.精准肝切除—21世纪肝脏外科新理念. 中华外科杂志,2009,47（21）:1601-1605.
[9] 马金良,李建生, 荚卫东, 等. 多层螺旋CT三维重建在肝脏肿瘤手术中的应用. 实用肝脏病杂志,2007,10（5）:296-297.
[10] 孙逊,许戈良,荚卫东,等. 3D虚拟手术规划系统在精准肝切除治疗肝细胞癌的临床应用. 国际外科学杂志,2014,41（8）:537-540.
[11] 李光耀,荚卫东,许戈良,等. 精准右半肝联合尾状叶肿瘤切除术. 中华消化外科杂志,2014,13（9）:726-729.
[12] 荚卫东,许戈良,马金良,等. 超声吸引刀结合单极电凝在原发性肝癌肝切除中的应用.临床外科杂志,2009,17（12）:824-827.
[13] 荚卫东,刘文斌,许戈良,等. 精细肝切除治疗原发性肝癌术后并发症的原因和防治. 国际外科学杂志,2012,39（4）:246-249.
[14] 荚卫东,乔晓斐. 精准肝脏外科时代无痛病房建设. 中华消化外科杂志,2014,13（6）:415-418.
[15] 荚卫东. 加速康复外科在精准肝脏外科中的应用.中华消化外科杂志,2015,14（1）:25-28.
[16] 许戈良, 荚卫东. 肝切除术中肝脏功能的影响因素及其评估.世界华人消化杂志,2010,18（35）:3721-3723.
[17] 苏昭然,荚卫东,许戈良,等. 肝切除术中吲哚青绿排泄试验预测术后肝功能不全的临床研究.中华普通外科杂志,2011,17（7）:618-620.
[18] NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. V2.2012：46.
[19] Llovet JM,Ducreux M,Lencioni R,et al. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatology,2012,56（4）：908-943.
[20] Morris-Stiff G,Gomez D,de Liguori Carino N,et al. Surgical management of hepatocellular carcinoma:is the jury still out? Surg Oncol,2009,18（4）:298-321.
[21] Iwadou S,Nouso K,Kuwaki K,et al. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int,2010,30（7）:1027-1032.
[22] Forner A,Reig ME,de Lope CR,et al. Current strategy for staging and treatment:the BCLC update and future prospects. Semin Liver Dis,2010,30（1）:61-74.
[23] Yin L,Li H,Li AJ,et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria:a RCT. J Hepatol,2014,61（1）:82-88.
[24] Llovet JM,Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol,2008,48（Suppl 1）:20-37.
[25] Choi KK,Kim SH,Choi SB,et al. Portal venous invasion:the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol,2011,26（11）:1646-1651.
[26] Demicheli R,Retsky MW,Hrushesky WJ,et al. The effects of surgery on tumor growth:a century of investigations. Ann Oncol,2008,19（11）:1821-1828.
[27] Sun YF,Xu Y,Yang XR,et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology,2013,57（4）:1458-1468.
[28] Li CX,Wong BL,Ling CC,et al. A novel oxygen carrier “YQ23” suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. BMC Cancer,2014,27（14）:293.
[29] 肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识. 中华肝脏病杂志,2014,22（5）:321-325.
[30] Sasaki A,Iwashita Y,Shibata K,et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol,2006,32（7）:773-779.
[31] Ren ZG,Lin ZY,Xia JL,et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor:a retrospective control study. World J Gastroenterol,2004,10（19）:2791-2794.
[32] Lammer J,Malagari K,Vogl T,et al. Prospective randomized study of oxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:Results of the PRECISION v study. Cardiovasc Intervent Radiol,2010,33（1）:41-52.
[33] Hasegawa K,Takayama T,Ijichi M,et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology,2006,44（4）:891-895.
[34] Xia Y,Qiu Y,Li J,et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection:a randomized controlled trial. Ann Surg Oncol,2010,17（12）:3137-3144.
[35] Qin S,Bai Y,Lim HY,et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol,2013,31（28）:3501-3508.
[36] Zhong JH,Li H,Li LQ,et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma:a systematic review of randomized trials. Eur J Surg Oncol,2012,38（4）:286-295.
[37] Ji J,Shi J,Budhu A,et al. MicroRNA expression,survival,and response to interferon in liver cancer. N Engl J Med,2009,361（15）:1437-1447.
[38] Mazzaferro V,Romito R,Schiavo M,et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology,2006,44（6）:1543-1554. [39] 张传海,荚卫东. 索拉非尼在肝癌治疗中的应用. 临床药学治疗杂志,2012,10（3）:24-26.
[40] Wilhelm SM,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res,2004,64（19）：7099-7109.
[41] 荚卫东,刘文斌. 高危复发因素肝细胞癌肝切除术后综合治疗. 世界华人消化杂志,2013,21（30）:3183-3189.

Multidisciplinary treatments for patients with hepatocellular carcinoma in the era of precise liver surgery

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.